Address: 50 Soldiers Field Place, Boston, MA 02135 (America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Download
| Disease | Type | Species |
|---|---|---|
| Obesity and diabetes | High-fat, high-sugar diet-induced obesity model | Mouse/Rat/Hamster |
| Streptozotocin-induced diabetes mellitus | Mouse/Rat | |
| Spontaneously diabetic mice db/db, ob/ob | db/db Mouse，ob/ob Mouse | |
| ZDF in spontaneously diabetic rats | ZDF Rat | |
| Hyperuricemia | Potassium oxyhydrogenate-induced hyperuricemia | Mouse/Rat |
| Adenine/hypoxanthine + potassium oxyhydrogenate induced hyperuricemia | Rat | |
| Uric acid-induced hyperuricemia | Mouse | |
| Hypoxanthine-induced hyperuricemia in mice | Mouse | |
| Adenine + ethambutol-induced hyperuricemia in rats | Rat | |
| Yeast-induced hyperuricemia | Mouse |
| Disease | Type | Species |
|---|---|---|
| NAFLD（NAFL / NASH） | HFD chow-fed model | Mouse/Rat/Hamster |
| MCD chow-fed model | Mouse | |
| Compound factor-induced model | Rat | |
| Liver Fibrosis | TAA-induced hepatic fibrosis | Rat |
| Compound factor approach induced liver fibrosis model | Rat | |
| ConA-induced liver fibrosis | Mouse | |
| Porcine serum-induced immunogenic liver fibrosis model | Rat |
Service Cases
Medicilon assists Beijing Peptide's clinical application of semaglutide injection of semaglutide was accepted by CDE; ZT002 was promoted in China, US and Australia Filing
Medicilon Assist – New progress in the field of NASH! Hepadin's HPD001 is about to start clinical trials in the U.S.
FAQNAFL:
It is completely reversible and can be completely reversed through a healthy lifestyle such as diet and exercise controlling diet, exercise and other healthy lifestyles. Drug therapy is mainly to improve lipid metabolism.
NASH:
It is a progressive form of nonalcoholic fatty liver disease, a metabolically stressful metabolic stress liver injury closely associated with insulin resistance and genetic predisposition, can progress to cirrhosis and hepatocellular carcinoma. It was also significantly associated with an increased risk of cardiovascular disease.
The etiology of NASH is complex, and the exact pathogenesis is unknown. There is no specific treatment or drug therapy for Nash.
NASH treatment drugs with different targets have become one of the current research and development hotspots, which target the different pathogenesis of NASH, such as liver metabolism, inflammation, oxidative stress, fibrosis, etc.
Relevant laboratories
Relevant articles
ABOUT
